Director, Forecasting (Lung)

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Senior Director, U.S. Forecasting, the Director, U.S. Forecasting will be responsible for developing and executing forecasting models and analyses that support product strategy, performance management, and operational planning. This role focuses on building and maintaining short-term demand forecasts and patient-based models across U.S. oncology assets, enabling manufacturing, supply chain, and commercial decision-making. The Director will partner closely with cross-functional stakeholders to align on forecast inputs, assumptions, and outputs, while ensuring high-quality, timely deliverables. As a key contributor within the U.S. Forecasting function, this individual will execute forecasting processes in alignment with the broader U.S. forecasting strategy and contribute to ongoing improvements in forecasting capabilities, tools, and data integration. This position is based at our Redwood City, CA headquarters, with flexibility for remote candidates willing to travel regularly to the office. Responsibilities include: Develop, maintain, and refine short-term demand forecasts across U.S. oncology products, including SKU-, dose-, and channel-level projections to support supply chain and commercial planning. Build and manage patient-based forecasting models incorporating oncology-specific dynamics such as incidence, biomarker segmentation, lines of therapy, treatment duration, and market evolution. Conduct scenario, sensitivity, and risk analyses to evaluate key business drivers and inform near-term decision-making. Translate complex data, assumptions, and model outputs into clear, actionable insights to support launch planning, performance tracking, and operational readiness. Partner cross-functionally with Commercial, Finance, Market Access, Medical Affairs, Supply Chain, and Manufacturing to gather inputs, validate assumptions, and ensure alignment on forecast outputs. Support development of production and inventory strategies by providing accurate and timely forecast updates and analyses. Integrate real-world data, secondary data sources (e.g., IQVIA), and competitive intelligence into forecasting models to enhance accuracy and responsiveness. Execute forecasting activities in alignment with U.S. Forecasting strategy and methodologies established by senior leadership, ensuring consistency and rigor. Support enhancements to forecasting processes, tools, and data infrastructure, including model standardization and automation initiatives. Maintain clear and transparent documentation of forecasting methodologies, assumptions, and data sources. Manage external vendors and data partners to ensure delivery of high-quality inputs and analyses. Escalate key risks, assumptions, and forecast variances to senior leadership with clear summaries and recommendations. Stay current on Revolution Medicines’ portfolio, competitive landscape, and evolving oncology market dynamics. Required Skills, Experience and Education: Bachelor’s degree in business, life sciences, statistics, or economics required; advanced degree (MBA, MS, MPH, or PhD) preferred. 8+ years of experience in pharmaceutical, biotechnology, or consulting roles, including at least 5 years in forecasting